Like firemen fighting fire with fire, researchers at the University of Illinois and the University of Massachusetts at Amherst have found a way to fool a bacteria's evolutionary machinery into programming its own death. Continue reading ...
MIT researchers have found that the pigments responsible for the blue-green stain of the mucus that clogs the lungs of cystic fibrosis (CF) patients are primarily signaling molecules that allow large clusters of the opportunistic infection agent, Pseudomonas aeruginosa, to organize themselves into structured communities. Continue reading ...
Management of Clostridium difficileinfection (CDI) in geriatric and pediatric populations can be challenging and complicated. Because of the observed increase in CDI incidence in many age groups, healthcare professionals need to be especially attuned to the individual needs of these patient populations. Continue reading ...
Evolving HIV viral strains and the adverse side effects associated with long-term exposure to current treatments propel scientists to continue exploring alternative HIV treatments. In a new study, a University of Missouri researcher has identified broad-spectrum aptamers. Aptamers are synthetic molecules that prevent the HIV virus from reproducing. Continue reading ...
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and MACROCHEM CORPORATION (OTC Bulletin Board: MACM) announced that the results of two Phase 3 studies of pexiganan for the topical treatment of mild diabetic foot infection were published in the December 15, 2008 issue of Clinical Infectious Diseases. The publication was authored by Benjamin A. Lipsky, M.D. Continue reading ...
Thursday, December 18, 2008
Cognitive Function May Be Affected By High Blood Pressure In The Elderly
Adding another reason for people to watch their blood pressure, a new study from North Carolina State University shows that increased blood pressure in older adults is directly related to decreased cognitive functioning, particularly among seniors with already high blood pressure. This means that stressful situations may make it more difficult for some seniors to think clearly. Dr. Continue reading ...
Australian scientists at CSIRO (Commonwealth Scientific and Industrial Research Organisation), have developed a new system to screen for compounds that can inhibit one of the processes that takes place during the progression of Alzheimer's disease. In a paper published in the November issue of the Journal of Alzheimer's Disease, folate is shown to be beneficial in the screening system. Continue reading ...
Abbott (NYSE: ABT) announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The 2.25 mm stent system would offer physicians an option for treating coronary artery disease in narrower vessels that is based on the proven efficacy, safety and deliverability of XIENCE V. Continue reading ...
Lantheus Medical Imaging, Inc. a worldwide leader in diagnostic imaging, announced today new data from a retrospective, multicenter, cohort study of over four million hospitalized patients that shows similar unadjusted mortality rates for patients receiving DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension enhanced resting echocardiography exams when compared with patients who did not receive DEFINITY. Continue reading ...
There are 700,000 people in the UK currently living with dementia. This number is expected to double by 2019, with 163,000 new cases of dementia occurring in England and Wales each year. In total, 42% of the UK population are affected by dementia - by way of knowing a close friend or family member with the condition. Continue reading ...
Very few species spontaneously develop the cognitive, behavioral and neuropathological symptoms of Alzheimer's disease (AD), yet AD research must progress at a more rapid pace than the rate of human aging. Therefore, in recent years, a variety of animal models have been created - from tiny invertebrates with life spans measurable in months to huge mammals that live several decades. Continue reading ...
Australian scientists at CSIRO (Commonwealth Scientific and Industrial Research Organisation), have developed a new system to screen for compounds that can inhibit one of the processes that takes place during the progression of Alzheimer's disease. In a paper published in the November issue of the Journal of Alzheimer's Disease, folate is shown to be beneficial in the screening system. Continue reading ...
Abbott (NYSE: ABT) announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The 2.25 mm stent system would offer physicians an option for treating coronary artery disease in narrower vessels that is based on the proven efficacy, safety and deliverability of XIENCE V. Continue reading ...
Lantheus Medical Imaging, Inc. a worldwide leader in diagnostic imaging, announced today new data from a retrospective, multicenter, cohort study of over four million hospitalized patients that shows similar unadjusted mortality rates for patients receiving DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension enhanced resting echocardiography exams when compared with patients who did not receive DEFINITY. Continue reading ...
There are 700,000 people in the UK currently living with dementia. This number is expected to double by 2019, with 163,000 new cases of dementia occurring in England and Wales each year. In total, 42% of the UK population are affected by dementia - by way of knowing a close friend or family member with the condition. Continue reading ...
Very few species spontaneously develop the cognitive, behavioral and neuropathological symptoms of Alzheimer's disease (AD), yet AD research must progress at a more rapid pace than the rate of human aging. Therefore, in recent years, a variety of animal models have been created - from tiny invertebrates with life spans measurable in months to huge mammals that live several decades. Continue reading ...
Subscribe to:
Posts (Atom)
